Idenix Pharmaceuticals Reports First Quarter 2013 Financial Results
April 30, 2013 16:05 ET
|
Idenix Pharmaceuticals
CAMBRIDGE, Mass., April 30, 2013 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of...
Idenix Reports Favorable Resistance Profile for IDX719, a Potent, Pan-Genotypic HCV NS5A Inhibitor, at EASL Meeting
April 24, 2013 08:00 ET
|
Idenix Pharmaceuticals
CAMBRIDGE, Mass., April 24, 2013 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of...
Idenix Announces Data Presentation at the 48th Annual Meeting of the European Association for the Study of the Liver (EASL)
April 08, 2013 16:05 ET
|
Idenix Pharmaceuticals
CAMBRIDGE, Mass., April 8, 2013 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human...
Idenix Pharmaceuticals Announces Decision by the United States Patent and Trademark Office Patent Trial and Appeal Board in the First Phase of the Interference
March 22, 2013 16:12 ET
|
Idenix Pharmaceuticals
CAMBRIDGE, Mass., March 22, 2013 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of...
Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
February 26, 2013 16:05 ET
|
Idenix Pharmaceuticals
CAMBRIDGE, Mass., Feb. 26, 2013 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc., (Nasdaq:IDIX) announced today that Idenix management will present a corporate overview at the Cowen and Company 33rd...
Idenix Pharmaceuticals Reports Fourth Quarter and Year Ended 2012 Financial Results
February 25, 2013 16:05 ET
|
Idenix Pharmaceuticals
CAMBRIDGE, Mass., Feb. 25, 2013 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human...
Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
February 05, 2013 16:05 ET
|
Idenix Pharmaceuticals
CAMBRIDGE, Mass., Feb. 5, 2013 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc., (Nasdaq:IDIX) announced today that Idenix management will present a corporate overview at the 15th Annual BIO CEO &...
Idenix Pharmaceuticals Provides Update on IDX184 and IDX19368 Development Programs
February 04, 2013 16:05 ET
|
Idenix Pharmaceuticals
CAMBRIDGE, Mass., Feb. 4, 2013 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human...
Idenix Pharmaceuticals Announces Collaboration With Janssen to Initiate Phase II All-Oral Combination Studies Including IDX719, Simeprevir (TMC435) and TMC647055 for the Treatment of Hepatitis C Virus (HCV)
January 28, 2013 07:00 ET
|
Idenix Pharmaceuticals
CAMBRIDGE, Mass., Jan. 28, 2013 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human...
Idenix Pharmaceuticals to Present at the 31st Annual J.P. Morgan Healthcare Conference
January 02, 2013 16:05 ET
|
Idenix Pharmaceuticals
CAMBRIDGE, Mass., Jan. 2, 2013 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX) announced today that Idenix management will present a corporate overview at the 31st Annual J.P. Morgan...